How we choose sources
Every survival or response number we publish is traced to its primary source: the peer-reviewed study that first reported it, cited by PubMed ID and DOI. We prefer primary literature over summaries. We do not take a statistic from an advocacy site and repeat it; if an organization quotes a number, we go to the study it is quoting and cite that. Where a claim has no primary source we can stand behind, we do not publish it as a fact.
How we handle conflicting evidence
Studies often disagree, usually because they enrolled different animals. When they do, we do not pick the most flattering number. We present a range, lead with the larger or more recent cohort, and carry each figure's cohort size and study design in the wording, because a median from a small retrospective review is not the same object as one from a randomised trial. We also explain, in plain language, why a median is a midpoint and not a prediction for any individual dog.
Who writes and reviews the content
Our content is written by the RosieVaccine team. We are candid about one gap: we do not yet have a board-certified veterinary oncologist reviewing these pages. Until we do, we do not claim veterinary review, and we do not attach a reviewer's name to anything they did not review. When a named veterinary oncologist reviews a page, we will say so, with their name and the date. Nothing here is a substitute for your own veterinarian.
What this content is, and is not
- It is general education for dog owners and their veterinary teams. It is not veterinary medical advice for your specific dog.
- It makes no claim of efficacy for any treatment, including our own. Where we describe research, we label its strength honestly.
- RosieVaccine's own work is a research-stage design service. There is no licensed or available product, and any future authorized use would run through the USDA Center for Veterinary Biologics pathway, not as an FDA-approved drug.
How to request a correction
If you believe something we published is wrong, tell us and we will look into it. Email privacy@rosievaccine.com with the page and the specific claim. When we correct a material error, we fix the page and update its "last modified" date. Getting the facts right matters more to us than being right the first time.
Our interest, disclosed
RosieVaccine is a company developing personalized mRNA cancer vaccines for dogs. We therefore have both a research interest and a financial interest in this field. We write about competing and standard treatments anyway, and we try to describe them fairly, but you should read anything we say about vaccines and immunotherapy with that stake in mind. Where we cite human or canine vaccine data, we state plainly whether it is human data, whether it is early-stage, and that no personalized cancer vaccine, including ours, has published canine efficacy data.